Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress 2023 EHA Congress 2023 ASCO Annual Meeting
Clinical Collections
Advances in Alzheimer’s

At a glance: The ONWARDS insulin icodec trials

A round-up of the ONWARDS phase 3 clinical trials evaluating the novel weekly insulin icodec in people with diabetes.
ADVANCED SEARCH
Log in
Top
Molecular Cancer
Published in: Molecular Cancer 1/2012

Open Access 01-12-2012 | Research

β3 integrin modulates transforming growth factor beta induced (TGFBI) function and paclitaxel response in ovarian cancer cells

Authors: David A Tumbarello, Jillian Temple, James D Brenton

Published in: Molecular Cancer | Issue 1/2012

Login to get access

Abstract

Background

The extracellular matrix (ECM) has a key role in facilitating the progression of ovarian cancer and we have shown recently that the secreted ECM protein TGFBI modulates the response of ovarian cancer to paclitaxel-induced cell death.

Results

We have determined TGFBI signaling from the extracellular environment is preferential for the cell surface αvβ3 integrin heterodimer, in contrast to periostin, a TGFBI paralogue, which signals primarily via a β1 integrin-mediated pathway. We demonstrate that suppression of β1 integrin expression, in β3 integrin-expressing ovarian cancer cells, increases adhesion to rTGFBI. In addition, Syndecan-1 and −4 expression is dispensable for adhesion to rTGFBI and loss of Syndecan-1 cooperates with the loss of β1 integrin to further enhance adhesion to rTGFBI. The RGD motif present in the carboxy-terminus of TGFBI is necessary, but not sufficient, for SKOV3 cell adhesion and is dispensable for adhesion of ovarian cancer cells lacking β3 integrin expression. In contrast to TGFBI, the carboxy-terminus of periostin, lacking a RGD motif, is unable to support adhesion of ovarian cancer cells. Suppression of β3 integrin in SKOV3 cells increases resistance to paclitaxel-induced cell death while suppression of β1 integrin has no effect. Furthermore, suppression of TGFBI expression stimulates a paclitaxel resistant phenotype while suppression of fibronectin expression, which primarily signals through a β1 integrin-mediated pathway, increases paclitaxel sensitivity.

Conclusions

Therefore, different ECM components use distinct signaling mechanisms in ovarian cancer cells and in particular, TGFBI preferentially interacts through a β3 integrin receptor mediated mechanism to regulate the response of cells to paclitaxel-induced cell death.
Appendix
Available only for authorised users
Literature
1.
Ahmed AA, Mills AD, Ibrahim AE, Temple J, Blenkiron C, Vias M, Massie CE, Iyer NG, McGeoch A, Crawford R: The extracellular matrix protein TGFBI induces microtubule stabilization and sensitizes ovarian cancers to paclitaxel. Cancer Cell. 2007, 12 (6): 514-527. 10.1016/j.ccr.2007.11.014PubMedCentralCrossRefPubMed
2.
Jazaeri AA, Awtrey CS, Chandramouli GV, Chuang YE, Khan J, Sotiriou C, Aprelikova O, Yee CJ, Zorn KK, Birrer MJ: Gene expression profiles associated with response to chemotherapy in epithelial ovarian cancers. Clin Cancer Res. 2005, 11 (17): 6300-6310. 10.1158/1078-0432.CCR-04-2682CrossRefPubMed
3.
Bull Phelps SL, Carbon J, Miller A, Castro-Rivera E, Arnold S, Brekken RA, Lea JS: Secreted protein acidic and rich in cysteine as a regulator of murine ovarian cancer growth and chemosensitivity. Am J Obstet Gynecol. 2009, 200 (2): e181-187. 180.
4.
Sherman-Baust CA, Weeraratna AT, Rangel LB, Pizer ES, Cho KR, Schwartz DR, Shock T, Morin PJ: Remodeling of the extracellular matrix through overexpression of collagen VI contributes to cisplatin resistance in ovarian cancer cells. Cancer Cell. 2003, 3 (4): 377-386. 10.1016/S1535-6108(03)00058-8CrossRefPubMed
5.
Giancotti FG, Ruoslahti E: Integrin signaling. Science. 1999, 285 (5430): 1028-1032. 10.1126/science.285.5430.1028CrossRefPubMed
6.
Thapa N, Lee BH, Kim IS: TGFBIp/betaig-h3 protein: a versatile matrix molecule induced by TGF-beta. Int J Biochem Cell Biol. 2007, 39 (12): 2183-2194. 10.1016/j.biocel.2007.06.004CrossRefPubMed
7.
Calaf GM, Echiburu-Chau C, Zhao YL, Hei TK: BigH3 protein expression as a marker for breast cancer. Int J Mol Med. 2008, 21 (5): 561-568.PubMed
8.
Zhao Y, El-Gabry M, Hei TK: Loss of Betaig-h3 protein is frequent in primary lung carcinoma and related to tumorigenic phenotype in lung cancer cells. Mol Carcinog. 2006, 45 (2): 84-92. 10.1002/mc.20167CrossRefPubMed
9.
Yamanaka M, Kimura F, Kagata Y, Kondoh N, Asano T, Yamamoto M, Hayakawa M: BIGH3 is overexpressed in clear cell renal cell carcinoma. Oncol Rep. 2008, 19 (4): 865-874.PubMed
10.
Schneider D, Kleeff J, Berberat PO, Zhu Z, Korc M, Friess H, Buchler MW: Induction and expression of betaig-h3 in pancreatic cancer cells. Biochim Biophys Acta. 2002, 1588 (1): 1-6. 10.1016/S0925-4439(02)00052-2CrossRefPubMed
11.
Buckhaults P, Rago C, St Croix B, Romans KE, Saha S, Zhang L, Vogelstein B, Kinzler KW: Secreted and cell surface genes expressed in benign and malignant colorectal tumors. Cancer Res. 2001, 61 (19): 6996-7001.PubMed
12.
Zhang Y, Wen G, Shao G, Wang C, Lin C, Fang H, Balajee AS, Bhagat G, Hei TK, Zhao Y: TGFBI deficiency predisposes mice to spontaneous tumor development. Cancer Res. 2009, 69 (1): 37-44. 10.1158/0008-5472.CAN-08-1648PubMedCentralCrossRefPubMed
13.
Swanton C, Nicke B, Schuett M, Eklund AC, Ng C, Li Q, Hardcastle T, Lee A, Roy R, East P: Chromosomal instability determines taxane response. Proc Natl Acad Sci U S A. 2009, 106 (21): 8671-8676. 10.1073/pnas.0811835106PubMedCentralCrossRefPubMed
14.
Kim JE, Kim SJ, Lee BH, Park RW, Kim KS, Kim IS: Identification of motifs for cell adhesion within the repeated domains of transforming growth factor-beta-induced gene, betaig-h3. J Biol Chem. 2000, 275 (40): 30907-30915.CrossRefPubMed
15.
Nam JO, Kim JE, Jeong HW, Lee SJ, Lee BH, Choi JY, Park RW, Park JY, Kim IS: Identification of the alphavbeta3 integrin-interacting motif of betaig-h3 and its anti-angiogenic effect. J Biol Chem. 2003, 278 (28): 25902-25909. 10.1074/jbc.M300358200CrossRefPubMed
16.
Ma C, Rong Y, Radiloff DR, Datto MB, Centeno B, Bao S, Cheng AW, Lin F, Jiang S, Yeatman TJ, Wang XF: Extracellular matrix protein {beta}ig-h3/TGFBI promotes metastasis of colon cancer by enhancing cell extravasation. Genes Dev. 2008, 22 (3): 308-321. 10.1101/gad.1632008PubMedCentralCrossRefPubMed
17.
Hashimoto K, Noshiro M, Ohno S, Kawamoto T, Satakeda H, Akagawa Y, Nakashima K, Okimura A, Ishida H, Okamoto T: Characterization of a cartilage-derived 66-kDa protein (RGD-CAP/beta ig-h3) that binds to collagen. Biochim Biophys Acta. 1997, 1355 (3): 303-314. 10.1016/S0167-4889(96)00147-4CrossRefPubMed
18.
Kim JE, Park RW, Choi JY, Bae YC, Kim KS, Joo CK, Kim IS: Molecular properties of wild-type and mutant betaIG-H3 proteins. Invest Ophthalmol Vis Sci. 2002, 43 (3): 656-661.PubMed
19.
Hanssen E, Reinboth B, Gibson MA: Covalent and non-covalent interactions of betaig-h3 with collagen VI. Beta ig-h3 is covalently attached to the amino-terminal region of collagen VI in tissue microfibrils. J Biol Chem. 2003, 278 (27): 24334-24341. 10.1074/jbc.M303455200CrossRefPubMed
20.
Billings PC, Whitbeck JC, Adams CS, Abrams WR, Cohen AJ, Engelsberg BN, Howard PS, Rosenbloom J: The transforming growth factor-beta-inducible matrix protein (beta)ig-h3 interacts with fibronectin. J Biol Chem. 2002, 277 (31): 28003-28009. 10.1074/jbc.M106837200CrossRefPubMed
21.
Kim BY, Olzmann JA, Choi SI, Ahn SY, Kim TI, Cho HS, Suh H, Kim EK: Corneal dystrophy-associated H124H mutation disrupts TGFBIinteraction with periostin and causes mislocalization to the lysosome. J Biol Chem. 2009.
22.
Reinboth B, Thomas J, Hanssen E, Gibson MA: Beta ig-h3 interacts directly with biglycan and decorin, promotes collagen VI aggregation, and participates in ternary complexing with these macromolecules. J Biol Chem. 2006, 281 (12): 7816-7824. 10.1074/jbc.M511316200CrossRefPubMed
23.
Kawamoto T, Noshiro M, Shen M, Nakamasu K, Hashimoto K, Kawashima-Ohya Y, Gotoh O, Kato Y: Structural and phylogenetic analyses of RGD-CAP/beta ig-h3, a fasciclin-like adhesion protein expressed in chick chondrocytes. Biochim Biophys Acta. 1998, 1395 (3): 288-292. 10.1016/S0167-4781(97)00172-3CrossRefPubMed
24.
Gillan L, Matei D, Fishman DA, Gerbin CS, Karlan BY, Chang DD: Periostin secreted by epithelial ovarian carcinoma is a ligand for alpha(V)beta(3) and alpha(V)beta(5) integrins and promotes cell motility. Cancer Res. 2002, 62 (18): 5358-5364.PubMed
25.
Takeshita S, Kikuno R, Tezuka K, Amann E: Osteoblast-specific factor 2: cloning of a putative bone adhesion protein with homology with the insect protein fasciclin I. Biochem J. 1993, 294 (Pt 1): 271-278.PubMedCentralCrossRefPubMed
26.
Horiuchi K, Amizuka N, Takeshita S, Takamatsu H, Katsuura M, Ozawa H, Toyama Y, Bonewald LF, Kudo A: Identification and characterization of a novel protein, periostin, with restricted expression to periosteum and periodontal ligament and increased expression by transforming growth factor beta. J Bone Miner Res. 1999, 14 (7): 1239-1249. 10.1359/jbmr.1999.14.7.1239CrossRefPubMed
27.
Bao S, Ouyang G, Bai X, Huang Z, Ma C, Liu M, Shao R, Anderson RM, Rich JN, Wang XF: Periostin potently promotes metastatic growth of colon cancer by augmenting cell survival via the Akt/PKB pathway. Cancer Cell. 2004, 5 (4): 329-339. 10.1016/S1535-6108(04)00081-9CrossRefPubMed
28.
Baril P, Gangeswaran R, Mahon PC, Caulee K, Kocher HM, Harada T, Zhu M, Kalthoff H, Crnogorac-Jurcevic T, Lemoine NR: Periostin promotes invasiveness and resistance of pancreatic cancer cells to hypoxia-induced cell death: role of the beta4 integrin and the PI3k pathway. Oncogene. 2007, 26 (14): 2082-2094. 10.1038/sj.onc.1210009CrossRefPubMed
29.
Malanchi I, Santamaria-Martinez A, Susanto E, Peng H, Lehr HA, Delaloye JF, Huelsken J: Interactions between cancer stem cells and their niche govern metastatic colonization. Nature. 2011, 481 (7379): 85-89. 10.1038/nature10694CrossRefPubMed
30.
Aoudjit F, Vuori K: Integrin signaling inhibits paclitaxel-induced apoptosis in breast cancer cells. Oncogene. 2001, 20 (36): 4995-5004. 10.1038/sj.onc.1204554CrossRefPubMed
31.
Ly DP, Zazzali KM, Corbett SA: De novo expression of the integrin alpha5beta1 regulates alphavbeta3-mediated adhesion and migration on fibrinogen. J Biol Chem. 2003, 278 (24): 21878-21885. 10.1074/jbc.M212538200CrossRefPubMed
32.
Borza CM, Pozzi A, Borza DB, Pedchenko V, Hellmark T, Hudson BG, Zent R: Integrin alpha3beta1, a novel receptor for alpha3(IV) noncollagenous domain and a trans-dominant Inhibitor for integrin alphavbeta3. J Biol Chem. 2006, 281 (30): 20932-20939. 10.1074/jbc.M601147200CrossRefPubMed
33.
Gonzalez AM, Claiborne J, Jones JC: Integrin cross-talk in endothelial cells is regulated by protein kinase A and protein phosphatase 1. J Biol Chem. 2008, 283 (46): 31849-31860. 10.1074/jbc.M801345200PubMedCentralCrossRefPubMed
34.
Yuan C, Reuland JM, Lee L, Huang AJ: Optimized expression and refolding of human keratoepithelin in BL21 (DE3). Protein Expr Purif. 2004, 35 (1): 39-45. 10.1016/j.pep.2003.12.020CrossRefPubMed
35.
Crowe J, Masone BS, Ribbe J: One-step purification of recombinant proteins with the 6xHis tag and Ni-NTA resin. Mol Biotechnol. 1995, 4 (3): 247-258. 10.1007/BF02779018CrossRefPubMed
36.
Pierschbacher MD, Ruoslahti E: Cell attachment activity of fibronectin can be duplicated by small synthetic fragments of the molecule. Nature. 1984, 309 (5963): 30-33. 10.1038/309030a0CrossRefPubMed
37.
Oh JE, Kook JK, Min BM: Beta ig-h3 induces keratinocyte differentiation via modulation of involucrin and transglutaminase expression through the integrin alpha3beta1 and the phosphatidylinositol 3-kinase/Akt signaling pathway. J Biol Chem. 2005, 280 (22): 21629-21637. 10.1074/jbc.M412293200CrossRefPubMed
38.
Cannistra SA, Ottensmeier C, Niloff J, Orta B, DiCarlo J: Expression and function of beta 1 and alpha v beta 3 integrins in ovarian cancer. Gynecol Oncol. 1995, 58 (2): 216-225. 10.1006/gyno.1995.1214CrossRefPubMed
39.
Liapis H, Adler LM, Wick MR, Rader JS: Expression of alpha(v)beta3 integrin is less frequent in ovarian epithelial tumors of low malignant potential in contrast to ovarian carcinomas. Hum Pathol. 1997, 28 (4): 443-449. 10.1016/S0046-8177(97)90033-2CrossRefPubMed
40.
Chen J, Zhang J, Zhao Y, Li J, Fu M: Integrin beta3 down-regulates invasive features of ovarian cancer cells in SKOV3 cell subclones. J Cancer Res Clin Oncol. 2009, 135 (7): 909-917. 10.1007/s00432-008-0526-8CrossRefPubMed
41.
Streuli CH, Akhtar N: Signal co-operation between integrins and other receptor systems. Biochem J. 2009, 418 (3): 491-506. 10.1042/BJ20081948CrossRefPubMed
42.
Morgan MR, Humphries MJ, Bass MD: Synergistic control of cell adhesion by integrins and syndecans. Nat Rev Mol Cell Biol. 2007, 8 (12): 957-969. 10.1038/nrm2289PubMedCentralCrossRefPubMed
43.
Kim JE, Jeong HW, Nam JO, Lee BH, Choi JY, Park RW, Park JY, Kim IS: Identification of motifs in the fasciclin domains of the transforming growth factor-beta-induced matrix protein betaig-h3 that interact with the alphavbeta5 integrin. J Biol Chem. 2002, 277 (48): 46159-46165. 10.1074/jbc.M207055200CrossRefPubMed
44.
Pierschbacher MD, Ruoslahti E: Variants of the cell recognition site of fibronectin that retain attachment-promoting activity. Proc Natl Acad Sci U S A. 1984, 81 (19): 5985-5988. 10.1073/pnas.81.19.5985PubMedCentralCrossRefPubMed
45.
Albini A, Allavena G, Melchiori A, Giancotti F, Richter H, Comoglio PM, Parodi S, Martin GR, Tarone G: Chemotaxis of 3 T3 and SV3T3 cells to fibronectin is mediated through the cell-attachment site in fibronectin and a fibronectin cell surface receptor. J Cell Biol. 1987, 105 (4): 1867-1872. 10.1083/jcb.105.4.1867CrossRefPubMed
46.
Kalra J, Warburton C, Fang K, Edwards L, Daynard T, Waterhouse D, Dragowska W, Sutherland BW, Dedhar S, Gelmon K, Bally M: QLT0267, a small molecule inhibitor targeting integrin-linked kinase (ILK), and docetaxel can combine to produce synergistic interactions linked to enhanced cytotoxicity, reductions in P-AKT levels, altered F-actin architecture and improved treatment outcomes in an orthotopic breast cancer model. Breast Cancer Res. 2009, 11 (3): R25 10.1186/bcr2252PubMedCentralCrossRefPubMed
47.
Ween MP, Lokman NA, Hoffmann P, Rodgers RJ, Ricciardelli C, Oehler MK: Transforming growth factor-beta-induced protein secreted by peritoneal cells increases the metastatic potential of ovarian cancer cells. Int J Cancer. 2011, 128 (7): 1570-1584. 10.1002/ijc.25494CrossRefPubMed
48.
Danen EH, Sonneveld P, Brakebusch C, Fassler R, Sonnenberg A: The fibronectin-binding integrins alpha5beta1 and alphavbeta3 differentially modulate RhoA-GTP loading, organization of cell matrix adhesions, and fibronectin fibrillogenesis. J Cell Biol. 2002, 159 (6): 1071-1086. 10.1083/jcb.200205014PubMedCentralCrossRefPubMed
49.
Puigvert JC, Huveneers S, Fredriksson L, op het Veld M, van de Water B, Danen EH: Cross-talk between integrins and oncogenes modulates chemosensitivity. Mol Pharmacol. 2009, 75 (4): 947-955. 10.1124/mol.108.051649CrossRefPubMed
50.
Partheen K, Levan K, Osterberg L, Claesson I, Fallenius G, Sundfeldt K, Horvath G: Four potential biomarkers as prognostic factors in stage III serous ovarian adenocarcinomas. Int J Cancer. 2008, 123 (9): 2130-2137. 10.1002/ijc.23758CrossRefPubMed
51.
Strobel T, Cannistra SA: Beta1-integrins partly mediate binding of ovarian cancer cells to peritoneal mesothelium in vitro. Gynecol Oncol. 1999, 73 (3): 362-367. 10.1006/gyno.1999.5388CrossRefPubMed
52.
Beauvais DM, Burbach BJ, Rapraeger AC: The syndecan-1 ectodomain regulates alphavbeta3 integrin activity in human mammary carcinoma cells. J Cell Biol. 2004, 167 (1): 171-181. 10.1083/jcb.200404171PubMedCentralCrossRefPubMed
53.
Davies EJ, Blackhall FH, Shanks JH, David G, McGown AT, Swindell R, Slade RJ, Martin-Hirsch P, Gallagher JT, Jayson GC: Distribution and clinical significance of heparan sulfate proteoglycans in ovarian cancer. Clin Cancer Res. 2004, 10 (15): 5178-5186. 10.1158/1078-0432.CCR-03-0103CrossRefPubMed
54.
Skonier J, Bennett K, Rothwell V, Kosowski S, Plowman G, Wallace P, Edelhoff S, Disteche C, Neubauer M, Marquardt H: beta ig-h3: a transforming growth factor-beta-responsive gene encoding a secreted protein that inhibits cell attachment in vitro and suppresses the growth of CHO cells in nude mice. DNA Cell Biol. 1994, 13 (6): 571-584. 10.1089/dna.1994.13.571CrossRefPubMed
55.
Kim JE, Kim SJ, Jeong HW, Lee BH, Choi JY, Park RW, Park JY, Kim IS: RGD peptides released from beta ig-h3, a TGF-beta-induced cell-adhesive molecule, mediate apoptosis. Oncogene. 2003, 22 (13): 2045-2053. 10.1038/sj.onc.1206269CrossRefPubMed
56.
Andersen RB, Karring H, Moller-Pedersen T, Valnickova Z, Thogersen IB, Hedegaard CJ, Kristensen T, Klintworth GK, Enghild JJ: Purification and structural characterization of transforming growth factor beta induced protein (TGFBIp) from porcine and human corneas. Biochemistry. 2004, 43 (51): 16374-16384. 10.1021/bi048589sCrossRefPubMed
57.
Irigoyen M, Pajares MJ, Agorreta J, Ponz-Sarvise M, Salvo E, Lozano MD, Pio R, Gil-Bazo I, Rouzaut A: TGFBI expression is associated with a better response to chemotherapy in NSCLC. Mol Cancer. 2010, 9: 130- 10.1186/1476-4598-9-130PubMedCentralCrossRefPubMed
58.
Ahmed AA, Wang X, Lu Z, Goldsmith J, Le XF, Grandjean G, Bartholomeusz G, Broom B, Bast RC: Modulating microtubule stability enhances the cytotoxic response of cancer cells to Paclitaxel. Cancer Res. 2011, 71 (17): 5806-5817. 10.1158/0008-5472.CAN-11-0025PubMedCentralCrossRefPubMed
Metadata
Title
β3 integrin modulates transforming growth factor beta induced (TGFBI) function and paclitaxel response in ovarian cancer cells
Authors
David A Tumbarello
Jillian Temple
James D Brenton
Publication date
01-12-2012
Publisher
BioMed Central
Published in
Molecular Cancer / Issue 1/2012
Electronic ISSN: 1476-4598
DOI
https://doi.org/10.1186/1476-4598-11-36

Other articles of this Issue 1/2012

Molecular Cancer 1/2012 Go to the issue

Research

Dichotomy effects of Akt signaling in breast cancer

Research

The RASSF gene family members RASSF5, RASSF6 and RASSF7 show frequent DNA methylation in neuroblastoma

Research

SNPs in the coding region of the metastasis-inducing gene MACC1 and clinical outcome in colorectal cancer

Review

The emerging role of histone lysine demethylases in prostate cancer

Research

Identification of cyclin B1 and Sec62 as biomarkers for recurrence in patients with HBV-related hepatocellular carcinoma after surgical resection

Research

Inhibition of HSP27 alone or in combination with pAKT inhibition as therapeutic approaches to target SPARC-induced glioma cell survival
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits